Microbiotica reported positive Phase Ib data for MB‑310, an oral live biotherapeutic for ulcerative colitis: 12 of 19 treated patients achieved clinical remission versus 3 of 10 on placebo, with sustained remission and resolution of rectal bleeding during a three‑month follow‑up. Responders also showed histological improvements and markers of mucosal healing. The firm said MB‑310 was generally well tolerated and the Phase Ib signal supports further development in larger trials. The readout adds momentum to the live‑microbiome therapeutic field and highlights potential for oral microbial consortia to induce mucosal healing in inflammatory bowel disease.